Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

Exogenous TSG-6 Treatment Alleviates DSS-Induced Colitis in Mice by Modulating Pou2f3 and Promoting Tuft Cells Differentiation

May 2, 2025

[Molecular Medicine] Scientists explored how TSG-6 regulated the intestinal epithelial barrier and its mechanistic role in experimental colitis.

Whole-Exome Tumor-Agnostic ctDNA Analysis Enhances Minimal Residual Disease Detection and Reveals Relapse Mechanisms in Localized Colon Cancer

May 2, 2025

[Nature Cancer] The authors performed whole-exome sequencing of circulating tumor DNA (ctDNA) at different time points in participants with relapsed colon cancer in two independent cohorts, alongside transcriptomic and proteomic analyses of metastases, to enhance comprehension of progression mechanisms.

Insights into Modeling Inflammatory Bowel Disease from Stem Cell Derived Intestinal Organoids

April 29, 2025

[Stem Cell Reviews and Reports] The authors consolidate current knowledge on inflammatory bowel disease pathogenesis and treatments, emphasizing the pivotal potential of human intestinal organoids as a robust platform for mechanistic studies and treatment exploration.

Diminution of HSP75 Disrupts Intestinal Epithelial Barrier by Inciting mPTP Opening in Ulcerative Colitis

April 29, 2025

[Cellular Signalling] Scientists ascertained that HSP75 was significantly diminished in the intestinal mucosa of ulcerative colitis patients and experimental colitis mice, concomitantly with the disruption of the intestinal epithelial barrier.

Vitamin D Enhances the Therapeutic Effect of TNF-α Antibodies through Lipid Metabolism in Overweight IBD Patients

April 29, 2025

[Cellular and Molecular Life Sciences] Investigators revealed that overweight inflammatory bowel disease patients present decreased vitamin D levels in the intestinal epithelium alongside elevated TNF-α levels.

β-Glucuronidase-Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity through Depleting the Regenerative Epithelial Stem/Progenitor Pool

April 29, 2025

[Advanced Science] Researchers explored the crosstalk between gut microbiota and intestinal stem cells in intestinal mucositis triggered by irinotecan chemotherapy.

Geographic and Age Variations in Mutational Processes in Colorectal Cancer

April 25, 2025

[Nature] Researchers investigated whether mutational processes contributed to geographic and age-related differences by examining 981 colorectal cancer genomes from 11 countries.

An Orally Administered Gene Editing Nanoparticle Boosts Chemo-Immunotherapy in Colorectal Cancer

April 25, 2025

[Nature Nanotechnology] Scientists developed an oral CRISPR–Cas9 delivery system based on zwitterionic and polysaccharide polymer-coated nanocomplexes that disrupted the tumor necrosis factor receptor-associated protein 1 gene in colorectal cancer.

TIPE3 Promotes Drug Resistance in Colorectal Cancer by Enhancing Autophagy via the USP19/Beclin1 Pathway

April 25, 2025

[Cell Death & Disease] Researchers investigated the function and mechanism of TIPE3 in drug resistance of colorectal cancer (CRC). TIPE3 expression in clinical samples and CRC cell lines was detected using qPCR.

Dual States of Murine Bmi1-Expressing Intestinal Stem Cells Drive Epithelial Development Utilizing Non-Canonical Wnt Signaling

April 25, 2025

[Developmental Cell] Scientists identified Bmi1⁺ cells as functional stem cells present in early murine intestinal development, prior to Lgr5-expressing intestinal stem cells (ISC)s. Lineage tracing and single-cell RNA sequencing identified that Bmi1⁺ ISCs could trace to Lgr5⁺ ISCs and other differentiated lineages.

QPS Expands Offerings With Robust Pharmacology Disease Models, Including MASH, Ulcerative Colitis, Wound Healing, and Psoriasis

April 25, 2025

[QPS (BioSpace)] QPS is pleased to announce the expansion of its pharmacology disease models portfolio to include highly relevant models for metabolic dysfunction-associated steatohepatitis (MASH), ulcerative colitis, wound healing, and psoriasis.

TREMFYA® (Guselkumab) Receives European Commission Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson’s Leadership in Inflammatory Bowel Disease

April 25, 2025

[Johnson & Johnson] Johnson & Johnson announced that the European Commission has approved a Marketing Authorisation for TREMFYA^® for the treatment of adult patients with moderately to severely active ulcerative colitis who had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.